Baird downgraded Frequency Therapeutics to Neutral from Outperform with a price target of 50c, down from $4. The all-stock merger transaction with Korro Bio expected to close in the fourth quarter of this year, the analyst tells investors in a research note. The firm downgraded Frequency ahead of the closure of the transaction.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on FREQ: